“I am delighted to welcome Université Paris Cité and AP-HP, Assistance Publique – Hôpitaux de Paris, to our Board of Directors as founding members behind the creation of the biocluster in 2023. Alongside the eight current public and private administrators, and in particular the Hospices Civils de Lyon – HCL and Claude Bernard Lyon 1 University, AP-HP and UPC will bring their academic and clinical expertise and the various collaborative platforms in which they are involved to the fight against emerging infectious diseases and antimicrobial resistance. With their arrival, the composition of the ID Cluster board of directors perfectly reflects the need to strengthen academic and industrial collaborations at the national and European level, in a One Health dimension” said Prof. Bruno Lina, President of Infectious Diseases Cluster.

“In 2022, AP-HP committed to a project to establish a French biocluster dedicated to the fight against infectious diseases. We are therefore delighted to join its board of directors, backed by our leading infectious disease services and extensive technical biology facilities, particularly in immunology and bacteriology. We also have numerous research support structures and are involved in several national platforms developed as part of the national IED and CBRN (chemical, biological, radiological and nuclear) threats strategy (IReivac émergence, OPEN-ReMlE, etc.) and the PEPR Bioproduction program. Awarded the Institut Carnot label in 2019 for the quality of its research partnerships with industrial players, AP-HP firmly believes that its participation in ID Cluster will strengthen synergies between academic, hospital, and industrial players, and also contribute to the rapid implementation of innovative solutions to respond to emerging health crises,” explains Milan LAZAREVIC, Director of Clinical Research and Innovation at AP-HP.

“Université Paris Cité, an active member of IDCluster’s application for Bioclusters France 2030, is delighted to join its administrators. UPCité will bring its academic expertise in emerging infectious diseases and antibiotic resistance to bear through more than 10 joint research units in the Faculty of Health and the Faculty of Science. In particular, UPCité runs the Graduate School One Health – Emerging Infectious Diseases, which brings together the faculties of Health, Sciences, and Societies and Humanities of Université Paris Cité, the Institut de physique du globe de Paris, the Institut Pasteur Institute, and the National Veterinary School of Alfort. In addition, UPCité will enable ID Cluster to benefit from its links with the AP-HP for the Reference Health Establishment for Epidemic and Biological Risk, the national COREB mission, and the Safeguard Pandemic Preparedness Institute project. We are strongly committed to developing academic-private partnerships with the pharmaceutical industry to stimulate and accelerate transfer and innovation capabilities,” adds Odile LAUNAY, University Professor of Infectious and Tropical Diseases at Université Paris Cité.

In this role, he will set up the ID360 Platform with all the founders and partners of IDCluster: national mapping of innovations currently under development in the fields of EID and AMR, and of the technological resources that can be mobilized to accelerate their development.

“I am honored to join IDCluster’s operational team and participate in this collaborative dynamic serving innovative projects that address the major infectious threats of our time,” explains Philippe Leissner. “Initially, I will focus my efforts on developing the ID360 Platform, which aims to become the leading platform in France for mapping advanced R&D projects, as well as expertise, resources, and technologies that can be mobilized in the fields of EID and AMR.”

Philippe graduated with a PhD in molecular biology from the University of Strasbourg and began his career at Transgene before joining bioMérieux, where he held several senior R&D positions in the fields of infectious diseases and precision medicine.

In 2016, he joined BIOASTER as Director of the Diagnostics program, where he developed numerous international collaborations with the healthcare industry, academia and NGOs. His work focuses on infectious diseases and antimicrobial resistance, both in high-income and developing countries.

Author of more than 35 scientific publications and patents, he now brings his expertise to the development of strategic partnerships to strengthen the work of the Infectious Diseases Cluster.

Following its “Bioclusters France 2030” label in May 2023, Bruno LINA, President of IDCluster, and Bpifrance signed the France 2030 aid agreement on March 30, 2025, with the support of the General Secretariat for Investment and the Health Innovation Agency.

This contract provides for the financing of IDCluster by the French State via BpiFrance from 2025 to 2030 for a maximum amount of €4,259,000, on an equal footing with the three founding industrial companies (Sanofi, bioMérieux, Ceva Santé Animale) and the members of IDCluster.

This funding, starting in May 2025, is dedicated to operating expenses, communication, and skills/expertise mobilized to accelerate R&D projects and technology platforms, in line with IDCluster’s mission to accelerate their market launch and use.

In return of this France 2030 funding, IDCluster’s leaders have committed in particular to:

• Demonstrating the biocluster’s openness to any R&D project that meets the eligibility criteria for the R&D project and technology platform acceleration program
• Demonstrate its ability to drive the French MIE and AMR ecosystem in order to develop responses to pandemic threats and their national and European visibility
• Accelerate at least 12 R&D projects before April 2030

Working alongside CEO Christophe JACQUINET, she will be responsible for coordinating the activities of the Infectious Diseases Cluster to identify and support innovative and collaborative projects in response to pandemic risks.

With a PhD in Immuno-Virology from the École Normale Supérieure de Lyon, Perrine Jeantet has successfully led innovative therapy development programs for 20 years in biotechnology companies, mainly in the field of infectious diseases.

Specializing in preclinical phases, she has led several complex therapy development programs, from design to preclinical validation, and has supported them through to clinical trials.

Throughout her career, she has led R&D teams, coordinated multidisciplinary teams, and leveraged her expertise through various patents, scientific publications, and national and international collaborations.